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1 These authors contributed equally to the work.Multiple mechanisms underlie the surprising willingness of mothers to tolerate the semi-allogeneic fetal
tissues during pregnancy. Chief among these is the expression of the HLA-G molecules that has been lar-
gely demonstrated to be responsible for reprogramming the local maternal immune response towards
tolerance. We recently identiﬁed a subset of tolerogenic dendritic cells, DC-10 that secrete high amounts
of IL-10 and express high levels of HLA-G and its ligand ILT4. DC-10 are present in the peripheral blood
and are essential in inducing adaptive regulatory T cells. We investigated the presence of DC-10 and HLA-
G-expressing CD4+ T cells in human decidua in the ﬁrst trimester of pregnancy. Results showed that these
cells are highly represented in human decidua as compared to the peripheral blood. This is the ﬁrst report
describing decidual DC-10 and CD4+HLA-G+ T cells, strongly suggesting that they may accumulate or be
induced at the fetal maternal interface to promote tolerance.
 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc.
Open access under CC BY-NC-ND license.1. Introduction
The fetus enjoys special privileges that minimize the risk of
being rejected by the maternal immune system during pregnancy.
The maternal immune system is alerted and responds actively to
the fetal invasion, but the type of inﬂammation generated is not
a milieu in which rejecting T cell responses are favored. At the fetal
maternal interface, the decidua serves as an immunologically priv-
ileged tissue playing essential functions in pregnancy maintenance
[1]. During the ﬁrst trimester of pregnancy, the majority of leuco-
cyte populations in the human decidua is composed of 70% natural
killer (NK) cells, and 10–20% antigen presenting cells (APCs) [2],
whereas T cells are sparse and B cells are virtually absent [2,3].tibility and Immunogenetics. Publi
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resenting 5–10% of all hematopoietic uterine cells [4]. DCs are not
only essential for the induction of primary immune responses but
also important for the establishment of immunological tolerance.
The local microenvironment inﬂuences the functions and differen-
tiation of DCs with tolerogenic activities that play a prominent role
in dictating the quantity and quality of immune responses [2]. Two
different myeloid DC subsets, BDCA-1+ and BDCA-3+, were detected
in normal human ﬁrst trimester decidua [5]. BDCA-1+ decidual
cells express HLA-DR, CD80 and CD86 at low levels, consistent with
the immature characteristics of myeloid DCs [6]. In addition, Kam-
merer et al. [3] have shown that early human pregnancy decidua
harbors C-type lectin-expressing cells (DC-SIGN+) that show func-
tional features of immature DCs.
During human pregnancy, non-classical HLA class I HLA-G pro-
teins, speciﬁcally expressed in the trophoblasts, contribute to the
establishment of immune tolerance [7]. Seven different isoforms
of HLA-G exist, four of which are membrane-bound (HLA-G1 to -
G4) and three are soluble forms (HLA-G5 to -G7). HLA-G locus is
low polymorphic in the coding region, but polymorphisms that
can regulate its expression are present at both 50 Up-stream Regu-
latory Region (URR) and 30 Un-translated Region (UTR) non-codingshed by Elsevier Inc. Open access under CC BY-NC-ND license.
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from interactions with diverse inhibitory receptors: directly via
Ig-like transcript (ILT)2 expressed on myeloid and lymphoid cells,
ILT4 speciﬁcally expressed on APCs, including DCs, and KIR2DL4
on NK cells and cytotoxic T lymphocytes (CTL); indirectly via
CD94/NKG2A on NK cells [9]. Myeloid APCs may express HLA-G
[10] and its expression is greatly enhanced by interferon-c, IL-10
and maturation stimuli [7].
The expression of membrane-bound HLA-G and the secretion of
soluble HLA-G by myeloid APCs contribute to the generation of a
tolerogenic microenvironment that may alter the functions of
HLA-G-expressing myeloid APCs (HLA-G+ APCs) themselves, in a
feedback loop. Thus, myeloid HLA-G+ APCs may be viewed as sup-
pressor cells capable of inhibiting other effector cells and of gener-
ating regulatory cells, such as tolerogenic DCs and regulatory T
cells (Tregs) [10]. Recently, a subset of IL-10-producing human
DC (DC-10) has been characterized in the peripheral blood [11].
These cells secrete high levels of IL-10, express membrane-bound
HLA-G, ILT2, ILT3, ILT4, and are potent inducers of adaptive IL-
10-producing type 1 Tregs (Tr1) in vitro through the IL-10-depen-
dent ILT4/HLA-G pathway [11].
CD4+ T cells constitutively expressingHLA-Ghave been shown to
accumulate at sites of inﬂammation [12]. It has been demonstrated
that CD4+HLA-G+ cells suppress T cell proliferation via a reversible
non-contact IL-10- and soluble HLA-G5-dependent process that
leads to regulation of tissue inﬂammation at the target organ [13].
In the present study we identify for the ﬁrst time the presence
of DC-10 and CD4+HLA-G+ T cells at the fetal maternal interface
where they may contribute to the tolerance establishment and
maintenance in the ﬁrst trimester decidua.
2. Materials and methods
2.1. Subjects and tissue samples
First trimester decidua (n = 10) at 6–12 weeks of gestational age
were obtained from Caucasian women with clinically normal preg-
nancies which were scheduled for elective abortion due to social or
psychological reasons. Peripheral blood was collected soon before
the aspiration procedure. Decidual tissues were taken through
the cervix during dilatation and aspiration according to formal
clinical procedures. Informed consent was obtained from all sub-
jects, and the investigation was approved by the Ethical Committee
of Fondazione IRCCS Ca’ Granda, Milan, Italy.
Human peripheral blood was obtained from healthy donors
upon informed consent in accordance with local ethical committee
approval (TIGET PERIBLOOD) and with the Helsinki Declaration.
Peripheral blood mononuclear cells (PBMC) were isolated by cen-
trifugation over Lymphoprep Ficoll gradients (Fresenius Kabi Nor-
ge AS, Halden, Norway).
This study was approved and monitored by the internal ethical
committee of the San Raffaele Scientiﬁc Institute and the Ethical
Committee of Fondazione IRCCS Ca’ Granda, Milan, Italy.
2.2. Isolation of mononuclear decidual cells
Samples were processed within 2 h after they have been col-
lected. Decidual tissues were dissected into small pieces and enzy-
matically dissociated in RPMI 1640 medium containing
collagenase type IV (1 mg/ml; Sigma Aldrich, Carlsbad, CA), and
DNase I (ﬁnal 0.01%, Invitrogen) for90 minat 37 Cwithgentle shak-
ing [14]. The suspension was ﬁltered through a 40-lm nylon mesh
(Cell Strainer, BD Biosciences, San Jose, CA). Decidual mononuclear
cells (DMNC)were separatedbydensitygradient centrifugationover
Lymphoprep Ficoll gradients (Fresenius Kabi Norge AS, Halden,
Norway).2.3. Flow cytometric analysis
DMNC and PBMC were initially incubated for 15 min at room
temperature with FcR blocking reagent (Miltenyi Biotech, Ger-
many) and stained for additional 30 min at room temperature with
the following human monoclonal Antibodies (mAbs): CD1c (BDCA-
1) and CD83 (Miltenyi Biotech, Germany), CD14, CD16, DC-SIGN,
CD11c, CD4, CD8 (BD Bioscience, CA), CD45 (BioLegend, USA),
ILT4 and CD56 (Beckman Coulter, France) and HLA-G (MEM-G9,
Exbio, Praha, Czech Republic). Cells were identiﬁed using a multi-
parametric approach based on the combination of mAbs. Samples
were acquired using a FACS Canto II ﬂow cytometer (Becton Dick-
inson, Mountain View, CA), and data were analyzed with FCS ex-
press (De Novo Software). Quadrant markers were set
accordingly to unstained controls.2.4. Statistical analysis
Values are reported as Mean ± SEM. Mann–Whitney test was
used to determine the statistical signiﬁcance of the data. Signiﬁ-
cance was deﬁned as ⁄p 6 0.05, ⁄⁄p 6 0.005, ⁄⁄⁄p 6 0.0005, and
⁄⁄⁄⁄p < 0.0001. Statistical calculations were performed with the
Prism program 5.0 (GraphPad Software, Inc. La Jolla, CA).3. Results and discussion
During pregnancy, subpopulations of leukocytes present at the
fetal-maternal interface change participating in a coordinated
manner to orchestrate sequential, reproductive events that result
in the maintenance of pregnancy [15]. During the ﬁrst trimester,
NK cells represent the most abundant immune cells in the decidua
[16]. These cells are CD56brightCD16, are distinct from peripheral
blood NK subsets [17], and are critical for the maintenance of preg-
nancy since their cytotoxicity is inhibited by the expression of
HLA-E and HLA-G on trophoblasts [16]. As expected, 58.3 ± 4.6%,
(mean ± SEM, n = 10) of the human decidual mononuclear cells
were CD56+ NK cells, of which >90% were CD16- (Fig. 1A).
The remainder decidual leukocyte population included T and B
lymphocytes, CD14+ monocytes, CD11b+ and CD11c+ myeloid cells.
In comparison with peripheral blood lymphocytes, the proportion
of CD4+ T cells inﬁltrating human decidua was signiﬁcantly lower
(16.01 ± 1.64%, mean ± SEM, n = 10, vs. 39.12 ± 3.83%, mean ± SEM,
n = 9, p = 0.0009) (Fig. 1B). No differences in the percentages of
CD8+ T cells, CD19+ B cells, and CD14+ monocytes were observed
between the human decidua and the peripheral blood.
Human decidual leukocytes contained also 6.4 ± 1.8% (mean ± -
SEM, n = 8) of CD11b+ cells, 49.95 ± 6.07% (mean ± SEM, n = 9) of
CD11c+ cells, and 3.54 ± 1.2%, (mean ± SEM, n = 9) of BDCA-1+
(CD11c+CD1c+) cells (Fig. 1C). The frequencies of decidual myeloid
CD11c+ and BDCA-1+ cellswere signiﬁcantly higher than their coun-
terpart in the peripheral blood of pregnant women (13.12 ± 1.74%,
mean ± SEM n = 9, p = 0.0027, and 0.69 ± 0.27, mean ± SEM, n = 9,
p = 0.0047, respectively) (Fig. 1C).Ourdataare in linewithaprevious
report demonstrating the presence of several subsets of DCs, includ-
ing BDCA-1+ (0.2%), in the human ﬁrst trimester decidua [5]; how-
ever, we found a higher percentage of decidual BDCA-1+ cells (3.5%).
Thismaybedue to themethodused for isolatingdecidua-inﬁltrating
cells: Ban et al. [5] used a non-enzymatic method, while we isolated
immune cells from decidual tissues by collagenase-mediated diges-
tion [14]. In addition, in the previous study the percentage of BDCA-
1+ cells was calculated based on total decidual cells, whereas we
evaluated the frequency of BDCA-1+ cells by gating on CD45+ cells.
In our setting, the percentage of CD45+ cells ranged from 10% to











































































Fig. 1. Analysis of immune cells inﬁltrating human decidua in the ﬁrst trimester of
pregnancy. Human decidua inﬁltrating cells were obtained by collagenase digestion
followed by gradient centrifugation. Percentages of CD56+, CD56+CD16+, and
CD56+CD16 cells (A), of CD4+, CD8+, CD19+, CD14+, and CD16+CD56 (B), CD11b+,
CD11c+, BDCA-1+ (CD11c+CD1c+) and DC-SIGN+ cells (C) in the peripheral blood and
human decidual leucocytes (gate on CD45+ cells) of pregnant women in the ﬁrst
trimester of pregnancy are presented. Percentages of positive cells (mean ± SEM)
are shown. ⁄p 6 0.05, ⁄⁄p 6 0.005, ⁄⁄⁄p 6 0.0005, and ⁄⁄⁄⁄p < 0.0001.
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cells that represents 6–10% of decidual cells [3,18]. Decidual DC-
SIGN+ cells have been shown to be immature myeloid cells [3]
and have been proposed to play a role in normal [3] and patholog-
ical pregnancy outcome [18]. In our setting, the percentage of
decidual DC-SIGN+ cells was 2.9 ± 0.6% (mean ± SEM, n = 8), and
their frequency was signiﬁcantly higher than that observed in
the peripheral blood of pregnant women (1.12 ± 0.23%, mean ± -
SEM n = 9, p = 0.01) (Fig. 1C).
DC-10 are tolerogenic DCs characterized by their ability to se-
crete IL-10 and by the high expression of membrane-bound HLA-
G [11]. Since DC-10 are highly potent in inducing Tr1 cells [11],
we hypothesized that these cells might represent one of the major
subsets of APCs present in the decidua involved in promoting and
maintaining tolerance during pregnancy. DC-10 were identiﬁed by
the concomitant expression of CD14, CD16 and CD83 on human
decidual leucocytes (CD45+). Interestingly, a signiﬁcantly higher
percentage of DC-10 was present in the human decidua than in
the peripheral blood of pregnant women (2.29 ± 0.75%, mean ± -
SEM, n = 10 vs. 0.25 ± 0.07%, mean ± SEM, n = 8, p = 0.0014)
(Fig. 2A). Human decidual DC-10 expressed similar levels of HLA-G, but signiﬁcantly lower levels of ILT4 (80.38 ± 2.45%, mean ± -
SEM, n = 10 vs. 96.38 ± 1.01%, mean ± SEM, n = 8; p = 0.0003) as
compared to circulating DC-10 (Fig. 2B). Similarly, inﬂammatory
monocytes (CD14+CD16) present in the human decidua expressed
similar levels of HLA-G but lower amounts of ILT4 as compared to
their circulating counterpart (56.86 ± 4.89%, mean ± SEM, n = 7 vs.
94.57 ± 1.23%, mean ± SEM, n = 9; p = 0.001, Fig. 2C). The expres-
sion of HLA-G and ILT4 on decidual BDCA-1+ cells was comparable
to that observed in their peripheral blood counterpart (Fig. 2C).
The increased frequency of DC-10 observed in the decidua may
be dependent on several mechanisms: DC-10 can be recruited from
the peripheral blood, resident decidual DCs can be converted into
DC-10, or the decidual microenvironment can promote the de novo
induction of DC-10. The decidual microenvironment is enriched of
several chemokines, including CCL2 [19] and CX3CL1 [20] that
have a role in tissue remodeling and in the recruitment of immune
cells. Peripheral blood DC-10 express CCR2 and CX3CR1 [11], thus
it can be hypothesized that they are attracted and accumulated in
the decidua. Several cytokines including IL-4, IL-10, and GM-CSF as
well as growth factors and hormones with anti-inﬂammatory
properties are present at the decidual level (reviewed in [21]). This
pro-tolerogenic microenvironment is known to promote alterna-
tively activated macrophages [22] and tolerogenic DCs [23]. In par-
ticular, the high levels of IL-10 may promote the up-regulation of
HLA-G, ILT2 and ILT4 on resident decidual immature DCs convert-
ing them into DC-10. Alternatively, the presence of GM-CSF, IL-4
and IL-10 can allow, through the IL-10 dependent ILT4/HLA-G
pathway, the de novo induction of tolerogenic DC-10. Further func-
tional studies are required to better deﬁne the origin and the role
of DC-10 in the decidua.
In addition to DCs, CD4+CD25+FOXP3+ Tregs are enriched at the
fetal-maternal interface [24,25] and are expanded accordingly to
gestational stages [26]. We conﬁrmed that CD4+CD25+FOXP3+
Tregs cells are present in the human decidua, and no differences
in the percentages of these cells were observed between human
decidua and peripheral blood in our cohort of pregnant women
(data not shown). In addition to CD4+CD25+FOXP3+ Tregs, other
Tregs either naturally occurring or induced have been described
[27]. Among them, we focused our attention on a new type of nat-
urally occurring CD4+ and CD8+ Tregs that constitutively express
HLA-G. CD4+HLA-G+ and CD8+HLA-G+ Tregs are present in the
peripheral blood [12]. Moreover, CD4+HLA-G+ Tregs have been
shown to accumulate at sites of inﬂammation, and are potent sup-
pressors of T cell proliferation in vitro [13]. To date, there is no evi-
dence of the presence of HLA-G-expressing CD4+ or CD8+ T cells in
the peripheral blood and the decidua during pregnancy. We ﬁrst
investigated the frequency of circulating CD4+HLA-G+ T cells in
pregnant women as compared to healthy donors. Results showed
a signiﬁcantly higher frequency of HLA-G expressing CD4+ T cells
in the peripheral blood of pregnant women (PBMC PW) compared
to that of healthy donors (PBMC HD) (5.29 ± 1.3%, mean ± SEM,
n = 8 vs. 2.13 ± 0.28%, mean ± SEM, n = 53, respectively,
p = 0.0053) (Fig. 3A). Interestingly, a distinct population of CD4+ T
cells expressing HLA-G was detected in the human decidua
(18.97 ± 2.98% mean ± SEM, n = 9) (Fig. 3A and B). The frequency
of CD8+HLA-G+ T cells in the human decidua was comparable to
that observed in the peripheral blood of pregnant women (data
not shown).
Similarly to what has been described in the central nervous sys-
tem [13], CD4+HLA-G+ T cells can be recruited to the human decid-
ua in the ﬁrst phases of embryo implantation to control immune
responses against the semi-allogeneic fetal antigens. It still re-
mains to be deﬁned whether decidual CD4+HLA-G+ T cells express
CCR5 or other chemokine receptors, which may allow their recruit-
ment into the decidua, in analogy to what has been described for
the same cells during the active inﬂammatory phase of multiple
AB
C
Fig. 2. Tolerogenic DC-10 are present at high frequency in the human decidua in the ﬁrst trimester of pregnancy. Human decidua inﬁltrating cells were obtained by
collagenase digestion followed by gradient centrifugation. (A) DC-10 were identiﬁed in the peripheral blood or in the human decidua according to CD14, CD16, and CD83
expression. Dot plots and histograms from one representative donor out of ten donors analyzed and the mean ± SEM of the percentages of positive cells are presented.
⁄⁄p 6 0.005. (B–C) Circulating and decidual DC-10, inﬂammatory monocytes, and BDCA-1+ cells expressing the tolerogenic markers HLA-G and ILT4. Peripheral blood and
human decidual cells were analyzed by ﬂow cytometry to determine levels of HLA-G and ILT4 expression. Analyses were performed on gated CD14+CD16+ cells in the
peripheral blood and CD45+CD14+CD16+ cells in the human decidua (B), gated CD14+CD16 cells (inﬂammatory monocytes) and CD1c+CD11c+ (BDCA-1+) cells in the
peripheral blood and CD45+CD14+CD16 cells (inﬂammatory monocytes) and CD45+CD1c+CD11c+ (BDCA-1+) cells in the human decidua (C). Dot plots from one
representative donor out of ten donors analyzed and the mean ± SEM of the percentages of inﬂammatory monocytes, and BDCA-1+ cells detected in all donors analyzed are
presented. ⁄⁄p 6 0.005 and ⁄⁄⁄p 6 0.0005.
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Fig. 3. High frequency of CD4+HLA-G+ T cells are present in the human decidua in the ﬁrst trimester of pregnancy. Human decidua inﬁltrating cells were obtained by
collagenase digestion followed by gradient centrifugation. Peripheral blood of healthy donors (PBMC HD) and of pregnant women (PBMC PW) as well as human decidua
inﬁltrating cells were analyzed by ﬂow cytometry to determine levels of HLA-G expression. Analyses were performed on gated CD4+ T cells in the peripheral blood and
CD45+CD4+ T cells in the human decidua, respectively. The mean ± SEM of the percentages of CD4+HLA-G+ T cells in all donors analyzed, ⁄⁄p 6 0.005 (A) and dot plots from one
representative donor out of ten donors analyzed are presented (B).
410 G. Amodio et al. / Human Immunology 74 (2013) 406–411sclerosis [13]. We cannot exclude that CD4+HLA-G+ T cells could be
directly induced in the decidua by local IL-10 as it is known that IL-
10 promotes HLA-G expression in CD4+ T cells [28]. Moreover, we
previously demonstrated that during Tr1 cell induction via DC-10,
IL-10-derived from DC-10 induces HLA-G expression on CD4+ T
cells that become anergic T cells, and subsequently Tr1 cells [11].
In this scenario, it can be speculated that naive CD4+ T cells, once
recruited in the decidua, can be activated via DC-10, up-regulate
HLA-G expression and then, in the continuous presence of IL-10
and chronic allo-speciﬁc stimulation, they become allo-speciﬁc
Tr1 cells. It still remains to deﬁne whether CD4+HLA-G+ T cells
are precursors of Tr1 cells or represent a distinct subset of Tregs,
which co-operate with other Tregs, including CD4+CD25+FOXP3+
Tregs, in promoting and maintaining fetal-maternal tolerance.4. Future perspectives
In addition to an overall improvement of the knowledge on the
biological mechanisms underlying tolerance associated with HLA-
G expression, our ﬁndings may have different potential clinical
implications. The ultimate goal of this study is the development
of a risk assessment of women with a history of recurrent implan-
tation failure who undergo in vitro fertilization (IVF). From a diag-
nostic point of view, the tolerance status of women with recurrent
embryo implantation failure after IVF can be evaluated. The analy-
sis of DC-10 and HLA-G+ Tregs and their potential association with
HLA-G polymorphisms will allow the identiﬁcation of speciﬁc HLA-
G genotypes that could be included among the pre-IVF screening
tests. From a therapeutic point of view, the study will open new
perspectives for the modulation of immune responses in the early
phases of pregnancy with the aim of minimizing the negative ef-
fects on embryo implantation associated with a reduced maternal
tolerance status.
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